Meeting medical needs through public-private collaboration
This article was originally published in Scrip
Executive Summary
Getting new drugs and vaccines to those who really need them is a problem that has taxed regulators, industry and activists for many years. It affects a wide range of areas, from drugs for neglected tropical diseases via medicines for TB and other infectious diseases, to targeted treatments for specific populations such as cancer patients. And while some successes have been achieved in meeting these unfilled needs, there is still some way to go.
You may also be interested in...
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.